PARIS -
- Trial Will Compare NXL103 With Leading Oral Agent Linezolid for the Treatment of Multi-Resistant Staphylococcus Aureus (MRSA) Infections
Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid (Zyvox, Pfizer NYSE:PFE).
The comparative Phase II trial with NXL103 is a prospective, multicenter, investigator-blinded, two-arm, parallel group study carried out in adults, either in hospital or as outpatients, with ABSSSI. Patients will be randomized to receive either NXL103 (500 mg twice a day) or linezolid (600mg twice a day), with 120 patients receiving NXL103 and 60 receiving linezolid. The treatment period in both study arms will be between 10 and 14 days.
The primary endpoint of the study is the clinical outcome in the clinically evaluable population at the Test of Cure (TOC) visit (7 days post-therapy). Secondary end points of the study include microbiological response at the TOC visit as well as evaluating the tolerability and safety of NXL103.
This comparative Phase II study is expected to recruit a total of 180 patients from approximately 20 sites in the USA and Central America. The study is expected to be completed in 2010 and is a critical part of Novexel’s clinical development plan for NXL103 which is focused on its potential to be used in hospitals and out-patients as an oral agent for the treatment of infections caused by Gram-positive organisms, including MRSA. Currently, physicians have a limited choice of anti-MRSA antibacterials when they wish to switch from intravenous (IV) to oral treatment, a key step prior to a patient being able to be discharged from the hospital.
NXL103, as a member of the Streptogramin class of antibiotics, has a unique mode of action, with its two components acting synergistically to inhibit the bacterial ribosome. Its spectrum of activity indicates its potential to be effective in the treatment of ABSSSI, including those caused by resistant pathogens such as MRSA.
In late 2008, Novexel announced positive results from a Phase II clinical trial evaluating NXL103 in the treatment of community acquired pneumonia (CAP).
Iain Buchanan, Novexel’s CEO, said, “The start of this Phase II trial with NXL103 is another important step in the growth of the company. There is a clear need for products that can be used to manage the release of patients from hospital by allowing them to be switched from intravenous to oral therapy.”
Notes to Editors
About NXL 103
NXL103 is a novel oral antibiotic made up of two streptogramin antibiotics, linopristin and flopristin, which act synergistically to inhibit the bacterial ribosome. NXL103 is a bactericidal antibiotic and in vivo studies have shown that this novel antibiotic is not affected by either beta-lactam or common macrolide resistance mechanisms. Positive results for a Phase II trial with NXL103 in the treatment of community acquired pneumonia (CAP) were reported towards the end of 2008. NXL103 is currently in a Phase II trial for the treatment of ABSSSI.
About ABSSSI
ABSSSI (Acute Bacterial Skin and Skin Structure Infections) are infections that involve deeper tissue or require surgical intervention (e.g. cellulitis, major cutaneous abscesses, and infected wounds) or are associated with a significant underlying disease that complicates response to therapy. A variety of pathogens may be identified in ABSSSI but the two most common Gram-positive pathogens are Staphylococcus aureus and Streptococcus pyogenes. The significant increase in the incidence of MRSA in community as well as hospital acquired infections has resulted in a need for empirical therapy of ABSSSI that is effective against MRSA.
About Novexel
Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel’s products are targeting the global hospital antibiotic market, which was worth an estimated $17bn in 2008.(1)
In addition to NXL103, Novexel is currently conducting two Phase II studies with NXL104 in combination with the cephalosporin antibiotic ceftazidime (CAZ/104) for serious Gram-negative infections. Patient recruitment in those studies (a) with complicated intra-abdominal infections (cIAIs) and (b) with complicated urinary tract infections (cUTIs) is nearing completion with the results expected in the first half of 2010.
A recent technical report from the European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMEA) entitled “The bacterial challenge: time to react,”(2) voiced the need to narrow the gap between multi-resistant bacteria in the EU and the development of new antibacterial agents. In particular the report highlighted the growing problem of infections caused by multi-resistant Gram negative bacteria including Pseudomonas aeruginosa. These are the types of infections that Novexel is targeting with CAZ/104.
Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by Novexel’s partner, Forest Laboratories (NYSE: FRX), solely for North American markets.
Novexel was created in December 2004 as an independent spin-out of the sanofi-aventis (Euronext Paris: SAN, NYSE: SNY) anti-infectives unit. Novexel has a team of 54 employees with significant experience in anti-infective research and development, who are located in Paris, France and Philadelphia, USA.
———————————
(1) Source: IMS Health, MIDAS, 2006-2008
(2) “The bacterial challenge: time to react, A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents”, ECDC/EMEA Joint Technical Report, September, 2009
For further information please contact: Novexel Gordon Waldron, CFO gordon.waldron@novexel.com Citigate Dewe Rogerson Amber Bielecka/David Dible/Nina Enegren Tel.: +44(0)207-638-95-71 amber.bielecka@citigatedr.co.uk
Source: Novexel
For further information please contact: Novexel, Gordon Waldron, CFO, gordon.waldron at novexel.com; Citigate Dewe Rogerson, Amber Bielecka/David Dible/Nina Enegren, Tel.: +44(0)207-638-95-71, amber.bielecka at citigatedr.co.uk
Related Press Releases
Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San FranciscoSeptember 10th, 2009 PARIS - Novexel, a specialty pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its pipeline will be the subject of 16 posters and one slide presentation at the 49th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The ICAAC meeting, which is taking place in San Francisco, California, September 12-15 2009, is the leading global conference on anti-microbial agents globally with over 10,000 participants.
NanoPass Makes its MicronJet Technology Available to Increase Global Supply of Pandemic Influenza VaccinesAugust 12th, 2009 NES ZIONA, Israel -
- Intradermal Delivery of Vaccines can Provide Significant Dose Sparing Urgently Required in the Swine H1N1 Pandemic
Following the World Health Organization (WHO) declaration of a swine flu pandemic,[1] NanoPass Technologies Ltd. (NanoPass) announced today that it has successfully developed a microneedle-based injection device that could dramatically enhance both the effectiveness and supply of pandemic flu vaccines.
Vitacreme B12 Vitamin Crème Proven to Revitalize SkinJuly 15th, 2009 KEMSING, England - E Pharm Limited has today launched the only cosmetic product with Vitamin B12 as the main active ingredient. Vitacreme B12 is a high-quality product formulated and made in Switzerland.
In a "David Against Goliath" Move, Cult Anti-Ageing Skincare Brand, SKIN.NY(R), Takes on Boots The Chemist for Misleading the Public by Making False Claims About Their No.7 Protect & Perfect ProductsMay 26th, 2009 LONDON - Cult skincare brand SKIN.NY(R) have issued legal proceedings against beauty giant, Boots the Chemist, for misleading the public. In a recent blaze of publicity, Boots the Chemist claimed that their much-lauded Boots No.7 Protect and Perfect was the first anti-wrinkle cream to be proven to be effective in clinical trials.
Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in HelsinkiMay 17th, 2009 PARIS - Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its two most advanced pipeline products NXL104 and NXL103 are the subject of four posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The ECCMID conference is taking place in Helsinki between 16th and 19th May 2009.
D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke PatientsMay 5th, 2009 REHOVOT, Israel - D-Pharm announced today that it has submitted IND and Special Protocol Assessment (SPA) packages to the US Food and Drug Administration (FDA), for its pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients. D-Pharm plans to initiate the trial later this year following FDA review of the IND and SPA.
Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical StudyMay 3rd, 2009 NAPA, California - 12-week study concludes that new cosmeceutical improves skin barrier function, erythema and lesions associated with rosacea -
Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that target the science of healthy aging, today announced that the clinical study entitled "Topical PRK-124 (0.125%) Lotion for Improving the Signs and Symptoms of Rosacea," has been published in the May issue of Journal of Drugs in Dermatology, a peer-reviewed dermatologic publication. "We are extremely pleased that the University of California, Irvine, study has been published in the Journal of Drugs in Dermatology," stated Frank Massino, Chairman and Chief Executive Officer of Senetek PLC.
Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen BushMarch 25th, 2009 PARIS - Novexel, a speciality pharmaceutical company focused on the
discovery and development of novel antibiotics designed to overcome the
significant global problem of microbial resistance, announces today the
appointment of Dr. Karen Bush to the Company's Scientific Advisory Board
(SAB).
BioCis Pharma Starts Phase IIa Trial in PsoriasisMarch 11th, 2009 TURKU, Finland - BioCis Pharma Ltd., a privately-held drug development company with its
headquarters in Turku, Finland, announced that it has begun a new Phase IIa
clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical
drug for dermatology. The double-blind, vehicle-controlled study is designed
to evaluate the tolerability, pharmacokinetics, and efficacy of the topical
product in a total of 18 subjects with mild to moderate plaque psoriasis.
TriPollar(TM) POSE(TM) Introduces the Non-Invasive Home-Use Solution to a Sculpted BodyMarch 10th, 2009 TEL AVIV - New Clinical Device for Body Generates Inch-Loss, Cellulite Reduction
and the Tightening of Lax Skin
Ultragen Ltd, innovators in the home aesthetic beauty market, announced
today the launch of a new skin tightening, collagen boosting, body contouring
device powered by professional TriPollar(TM) RF technology, adapted for use
at home. The TriPollar(TM) POSE(TM) clinical skin tightening device for body.
Related News
Simple household whitener bleaches kids of chronic eczema tooApril 28th, 2009 WASHINGTON - Simple household bleach is best known for whitening a load of laundry, but it is also surprisingly effective in getting rid of chronic eczema in children. Chronic, severe eczema can mar childhood.
Newborn baby inspires wonder skin creamMarch 18th, 2009 LONDON - Even months after being in the womb, a baby's skin is unmatched for smoothness, thanks to vernix caseosa (VC), which covers the foetus and the newborn and aids in the growth of skin both before and after birth. Now scientists know why.
Professional Cricketers Association's members to be screened for skin cancerMay 15th, 2009 LONDON - All Professional Cricketers Association's (PCA) members will be screened for skin cancer for the first time. According to a BBC report, the union has organized the programme after one in seven county players were referred to specialists when potential melanomas were found during check-ups.
Riddhima Kapoor brand ambassador for Kaya Skin ClinicApril 14th, 2009 NEW DELHI - Riddhima Kapoor Sahni, daughter of actors Neetu and Rishi Kapoor, has become the brand ambassador for Kaya Skin Clinic. 'Every woman wants to look and feel beautiful.
Bleach baths may help treat kids' eczemaApril 27th, 2009 WASHINGTON - The simple household bleach is not only useful in whitening a load of laundry, but it can also turn out to be an effective treatment for kids' chronic eczema, according to a new study. Eczema is characterised by severe itching, which is so bad that kids may break the skin from scratching and get chronic skin infections that are difficult to treat, especially from methicillin-resistant Staphylococcus aureus (MRSA).
Medieval-style 'rack' that stretches skin grafts may help treat burns and woundsMay 11th, 2009 LONDON - Scientists have stretched slivers of skin to twice their size in a week using a robotic bioreactor that is akin to a medieval rack, a technique that could increase the size, viability and availability of skin grafts for treating burns and wounds. At present, skin grafts can be expanded by making cuts in them to create a mesh, or by inserting balloons under the graft once it has been attached to the body.
Tea tree oil, silver act like antiseptics when combinedMarch 30th, 2009 LONDON - Tea tree oil and silver, when combined and applied to infected skin wounds, seem to act like a potent antiseptic. Both tea tree oil and silver (as silver nitrate) are effective singly against a range of micro-organisms, but combining them in low doses boosted their antimicrobial activity, said Li Low and colleagues from University of Wolverhampton.
1yr-old girl being given date-rape drug to relieve skin disease painAugust 1st, 2009 LONDON - Parents of a one-year-old baby girl have to give her a date-rape drug to ease her from the pain caused by a rare skin disease, which makes her skin as fragile as a butterfly's wing. Isla Grist's skin starts to blister and bleed with the slightest touch and she screams in pain when her bandages are changed.
Immune cell could improve treatment of viral skin infectionApril 13th, 2009 SYDNEY - The local action of immune cells in the skin could improve treatment of viral infections, according to a recent discovery. A new study identifies previously unrecognised first-line defence mechanisms that are particularly important in the skin and the gut, often used as entry points by viruses and bacteria.
Common anticoagulant may cause skin lesionsSeptember 29th, 2009 WASHINGTON - Heparin, a commonly used anticoagulant, may cause skin lesions, a new study has found. Published in CMAJ (Canadian Medical Association Journal), the study looked at 320 patients undergoing heparin injections over 12 months at The Hospital of The Johann Wolfgang Goethe University in Frankfurt, Germany.
